Riskpilot← Back to searchSign inGet full accessAsimedicin AB
ABActiveOrg 5591922884Paradistorget 12Medical specialists activities · NACE 8622Est. 20190 employees
Revenue 2025
SEK 1,7M
-42% vs 2024
EBITDA margin
54.6%
-64% vs 2024
Equity ratio
49.1%
Financial strength
Net profit 2025
SEK 274K
-79% vs 2024
| Revenue | SEK 1,7M | -42% |
| EBITDA | SEK 909K | -64% |
| Net profit | SEK 274K | -79% |
| Total assets | SEK 7,9M | -27% |
| Equity | SEK 3,9M | +8% |
| Employees | 0 | — |
Legal name
Asimedicin AB
Org number
5591922884
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
24 januari 2019
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-03-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Företaget skall bedriva import och export av läkemedel samt import och export av livsmedel och förvalta fastigheter.
Address
Paradistorget 12
Email
asiaali70@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 397 | 969 | 2 473 | 2 870 | 1 666 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 526 | 1 013 | 2 444 | 2 542 | 909 |
| Depreciation & amort. | −121 | −121 | −0 | −153 | −153 |
| EBIT | 405 | 892 | 2 444 | 2 389 | 756 |
| Net financials | −78 | −188 | −94 | −165 | −102 |
| Profit before tax | 327 | 704 | 1 763 | 1 662 | 420 |
| Tax | −70 | −145 | −363 | −347 | −146 |
| Net profit | 257 | 559 | 1 400 | 1 315 | 274 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 6 461 | 6 831 | 9 087 | 10 769 | 7 878 |
| Equity | 319 | 879 | 2 279 | 3 594 | 3 868 |
| Long-term debt | 5 836 | 5 255 | 5 015 | 4 725 | 1 890 |
| Short-term debt | 306 | 697 | 1 207 | 1 303 | 737 |
| Total debt | 6 142 | 5 952 | 6 222 | 6 028 | 2 627 |
EBITDA margin
54.6%
This company
15.8%
Market median
+246% vs market
20212025
Equity ratio
49.1%
This company
38.2%
Market median
+29% vs market
20212025
Return on equity
7.1%
This company
18.4%
Market median
-61% vs market
20212025
Net profit margin
16.4%
This company
8.1%
Market median
+102% vs market
20212025
Asset turnover
0.21×
This company
1.12×
Market median
-81% vs market
20212025
Debt / equity
1.04×
This company
0.62×
Market median
-68% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-04-01 – 2025-03-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-04-01 – 2024-03-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-04-01 – 2023-03-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-04-01 – 2022-03-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-04-01 – 2021-03-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2021 | |
| Board of Directors | 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
KIDDS AB
Asimedicin AB Board members of Asimedicin AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Yassin Ibrahim Hassan Farrah | Deputy Board Member | 0 companies |
| Asia Ali Mohamed | Board of Directors | 0 companies |